Pharmacological prophylaxis for venous thromboembolism: Is it time to change the gold standard?

por Kumaraswamy, Santosh
Publicado 2021

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial

por Kumaraswamy, Santosh
Publicado 2021

Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma

por Kumaraswamy, Santosh
Publicado 2021

Re: Sharma PK, Panaiyadiyan S, Kurra S, Kumar R, Nayak B, Singh P, et al. Association of human papillomavirus in penile cancer: A single-center analysis. Indian J Urol 2022;38(3):...

por Ram, Prasanna, Kumaraswamy, Santosh, Mandal, Swarnendu, Das, Manoj K, Tripathy, Sambit, Nayak, Prasant
Publicado 2022

Socio-economic, education, and insurance-related factors associated with the treatment completion rates in patients with nonmetastatic urinary bladder cancer: A Retrospective cohor...

por Rohith, Gorrepati, Gaur, Abhay Singh, Nayak, Prasant, Mandal, Swarnendu, Das, Manoj K., Kumaraswamy, Santosh, Tarigopula, Vivek, Tripathy, Sambit
Publicado 2023